Tuesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
PAH is high blood pressure in your pulmonary arteries, which carry oxygen-poor blood from your heart to the lungs.
Merck added sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021.
Winrevair is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation ...